Legha S S, Buzdar A U, Smith T L, Hortobagyi G N, Swenerton K D, Blumenschein G R, Gehan E A, Bodey G P, Freireich E J
Ann Intern Med. 1979 Dec;91(6):847-52. doi: 10.7326/0003-4819-91-6-847.
One hundred sixteen patients with metastatic breast cancer who achieved complete remission with combination chemotherapy were analyzed to ascertain the factors that affect the duration of complete remission and the patterns of relapse. The median duration of complete remission was 17 months. Disease recurred in 81 patients (70%) at periods ranging from 3 to 44 months after achievement of complete remission. The duration of complete remission was inversely related to the bulk of metastatic tumor. Twenty-three patients treated with combined oophorectomy and chemotherapy experienced the longest remissions (median duration of 33 months); only eight (35%) of them have relapsed. Seventy-six percent of the relapses occurred in previously known sites of tumor involvement; most of the remainder involved the brain. The short duration of complete remissions and tendency to relapse in sites of initial involvement suggest that patients with metastatic breast cancer who achieved complete remission with combination chemotherapy still had substantial residual tumor. Consolidation treatments, using hormonal therapy and non-cross-resistant chemotherapy along with irradiation to initial sites of metastases, whould be investigated to ascertain their usefulness in prolonging the remissions.
对116例经联合化疗取得完全缓解的转移性乳腺癌患者进行分析,以确定影响完全缓解持续时间的因素及复发模式。完全缓解的中位持续时间为17个月。81例患者(70%)在完全缓解后3至44个月期间复发。完全缓解的持续时间与转移性肿瘤的大小呈负相关。23例接受卵巢切除术联合化疗的患者缓解期最长(中位持续时间为33个月);其中仅8例(35%)复发。76%的复发发生在先前已知的肿瘤受累部位;其余大部分累及脑部。完全缓解期短且倾向于在初始受累部位复发表明,经联合化疗取得完全缓解的转移性乳腺癌患者仍有大量残留肿瘤。应研究采用激素治疗、非交叉耐药化疗以及对转移初始部位进行放疗的巩固治疗,以确定其在延长缓解期方面的作用。